SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Teraa M.)
 

Sökning: WFRF:(Teraa M.) > Management of Cardi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003651naa a2200493 4500
001oai:lup.lub.lu.se:55394e60-a904-4005-9a34-84a3885a18fc
003SwePub
008160401s2011 | |||||||||||000 ||eng|
024a https://lup.lub.lu.se/record/23484072 URI
024a https://doi.org/10.1016/S1078-5884(11)60011-72 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
100a Diehm, N.4 aut
2451 0a Management of Cardiovascular Risk Factors and Medical Therapy
264 1c 2011
520 a Critical limb ischaemia (CLI) is a particularly severe manifestation of lower limb atherosclerosis posing a major threat to both limb and life of affected patients. Besides arterial revascularisation, risk-factor modification and administration of antiplatelet therapy is a major goal in the treatment of CLI patients. Key elements of cardiovascular risk management are smoking cessation and treatment of hyperlipidaemia with dietary modification or statins. Moreover, arterial hypertension and diabetes mellitus should be adequately treated. In CLI patients not suitable for arterial revascularisation or subsequent to unsuccessful revascularisation, parenteral prostanoids may be considered. CLI patients undergoing surgical revascularisation should be treated with beta blockers. At present, neither gene nor stem-cell therapy can be recommended outside clinical trials. Of note, walking exercise is contraindicated in CLI patients due to the risk of worsening pre-existing or causing new ischaemic wounds. CLI patients are oftentimes medically frail and exhibit significant comorbidities. Co-existing coronary heart and carotid as well as renal artery disease should be managed according to current guidelines. Considering the above-mentioned treatment goals, interdisciplinary treatment approaches for CLI patients are warranted. Aim of the present manuscript is to discuss currently existing evidence for both the management of cardiovascular risk factors and treatment of co-existing disease and to deduct specific treatment recommendations. (C) 2011 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng
653 a Conservative treatment
653 a Medication
653 a Risk factor modification
700a Schmidli, J.4 aut
700a Setacci, C.4 aut
700a Ricco, J. -B.4 aut
700a de Donato, G.4 aut
700a Becker, F.4 aut
700a Robert-Ebadi, H.4 aut
700a Cao, P.4 aut
700a Eckstein, H. H.4 aut
700a De Rango, P.4 aut
700a Teraa, M.4 aut
700a Moll, F. L.4 aut
700a Dick, F.4 aut
700a Davies, A. H.4 aut
700a Lepantalo, M.4 aut
700a Apelqvist, Janu Lund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups4 aut0 (Swepub:lu)endo-jap
710a Genomik, diabetes och endokrinologib Forskargrupper vid Lunds universitet4 org
773t European Journal of Vascular and Endovascular Surgeryg 42:Suppl. 2, s. 33-42q 42:Suppl. 2<33-42x 1532-2165
856u http://dx.doi.org/10.1016/S1078-5884(11)60011-7y FULLTEXT
8564 8u https://lup.lub.lu.se/record/2348407
8564 8u https://doi.org/10.1016/S1078-5884(11)60011-7

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy